Clinical and prognostic significance of lost or decreased PDCD5 expression in human epithelial ovarian carcinomas

Abstract

Abstract. Programmed cell death 5 (PDCD5) is a novel apoptosis-promoting protein. Although the decreased expression of PDCD5 has been recently found in a few types of human tumors, the status and significance of PDCD5 in ovarian cancer has not been evaluated. In the present study, we detected PDCD5 expression in 20 normal human ovaries and 26 serous cystadenomas and 41 serous cystadenocarcinomas by RT-PCR, Western blotting and immunohistochemistry, and analyzed the relationship between PDCD5 expression and clinicopathological data or patient survival. PDCD5 was expressed in all normal ovaries and serous cystadenomas, 80% (16/20) of normal ovarian tissues and 76.9% (20/26) of serous cystadenomas with moderate or strong PDCD5 protein expression. In contrast, 22% (9/41) of serous cystadenocarcinomas had no detectable PDCD5 protein expression and 46.3% (19/41) exhibited weak PDCD5 expression. The overall expression of PDCD5 in serous cystadenocarcinoma was significantly lower compared with normal ovarian tissues or serous cystadenomas (p<0.01). Furthermore, lost or decreased PDCD5 expression in serous cystadenocarcinomas was associated significantly with FIGO stage (p<0.05) and poorer diseasespecific survival of patients (p<0.05). In conclusion, our data suggest that lost or reduced PDCD5 expression may contribute to the pathogenesis of human serous cystadenocarcinomas.

PDCD5 regulates cell proliferation, cell cycle progression and apoptosi

“…PDCD1, often known as PD-1, is the member that has been most extensively studied and shown to negatively regulate T cell responses, in collaboration with its two ligands, PD-L1 and PD-L2 (51)(52)(53). In addition to PDCD5, other programmed cell death proteins are also known to play important roles in apoptosis and/or cell cycle progression (54)(55)(56)(57), and are also dysregulated in many types of human cancers (13,16,(58)(59)(60)(61)(62)(63). Opposite to what we observed for PDCD5, depletion of PDCD2 in human acute leukemia cells impairs their proliferation, induces cell cycle arrest and p53 activation while overexpression of PDCD2 facilitates cell growth in cancers (55,64).…”

“…More recently, it was reported that PDCD5 also regulates autophagy to protect against cardiac remodeling (12). Dysregulation of PDCD5 has been found to be involved in different type of tumors (13)(14)(15)(16)(17)(18)(19)(20)(21)(22). The antitumor activity of PDCD5 has been also proposed (23)(24)(25)(26)(27)(28)(29) and low expression level of PDCD5 has been suggested to be a prognostic indicator for cancers (30).…”

PDCD5 promotes cisplatin-induced apoptosis of glioma cells via activating mitochondrial apoptotic pathway

“…11 The reduced expression of PDCD5 correlates with short survival periods of patients. 8,[12][13][14] Furthermore, it has been found that two single-nucleotide polymorphisms with linkage disequilibrium in the 5'-regulatory region of human PDCD5 gene reduce its promoter activity and increase susceptibility to chronic myeloid leukemia. 15,16 A single-nucleotide polymorphism in the 5'-upstream region of PDCD5 gene is predictive for lung cancer risk and prognosis.…”

Construction and characterization of a PDCD5 recombinant lentivirus vector and its expression in tumor cells

“…In fact, PDCD5 expression decreases with increased tumor stage, reduced differentiation status, and metastasis to lymph nodes (2-7). Therefore, decreased PDCD5 gene expression is associated with poor prognosis of ovarian carcinoma, chondrosarcoma, and glioma (2,3,5). A combination of both in vitro and in vivo experiments confirmed that tumor cells expressing PDCD5 or treated with recombinant PDCD5 protein were more sensitive to chemotherapeutic drugs and UV irradiation.…”